Center for Discovery & Innovation, Hackensack Meridian Health, Cancer Prevention Precision Control Institute, 111 Ideation Way, Nutley, NJ, 07110, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
BMC Public Health. 2023 May 26;23(1):975. doi: 10.1186/s12889-023-15857-8.
Lung cancer is the leading cause of cancer death for both men and women in the United States. The National Lung Screening Trial (NLST) demonstrated that low-dose computed tomography (LDCT) screening can reduce lung cancer mortality among high-risk individuals, but uptake of lung screening remains low. Social media platforms have the potential to reach a large number of people, including those who are at high risk for lung cancer but who may not be aware of or have access to lung screening.
This paper discusses the protocol for a randomized controlled trial (RCT) that leverages FBTA to reach screening-eligible individuals in the community at large and intervene with a public-facing, tailored health communication intervention (LungTalk) to increase awareness of, and knowledge about, lung screening.
This study will provide important information to inform the ability to refine implementation processes for national population efforts to scale a public-facing health communication focused intervention using social media to increase screening uptake of appropriate, high-risk individuals.
The trial is registered at clinicaltrials.gov (#NCT05824273).
肺癌是美国男性和女性癌症死亡的主要原因。国家肺癌筛查试验（NLST）表明，低剂量计算机断层扫描（LDCT）筛查可以降低高危人群的肺癌死亡率，但肺癌筛查的参与率仍然很低。社交媒体平台有可能接触到大量的人，包括那些肺癌风险高但可能不知道或无法获得肺癌筛查的人。
本文讨论了一项随机对照试验（RCT）的方案，该试验利用 FBTA 接触到广大社区的筛查合格者，并通过面向公众的、量身定制的健康传播干预（LungTalk）来提高对肺癌筛查的认识和了解。
这项研究将提供重要信息，为利用社交媒体提高适当、高危人群的筛查参与度，对全国人口努力实施以公众为导向的健康传播为重点的干预措施进行精细化实施过程提供信息。
该试验在 clinicaltrials.gov 注册（#NCT05824273）。
